Broker's Call: Lupin (Accumulate)
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Lupin’s Q2-FY27 EBITDA fell 8 per cent to ₹1,960 crore, matching analyst estimates.
- ✓While revenues grew 14 per cent to ₹7,780 crore, competition in key products like gTolvaptan remains a concern.
- ✓The company maintains an "Accumulate" rating with a target price of ₹2,250 as it focuses on its niche pipeline.
Story at a Glance
- Category
- BUSINESS
- Reported By
- Business Line
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
Lupin's Q2-FY27 EBITDA stood at ₹1,960 crore (down 8 per cent year on year) in line with our estimates.
Currently, three products (gTolvaptan, gMirabegron and gSpiriva) contribute about 50 per cent to total EPS. Competition in gTolvaptan has increased, whereas competition is likely to intensify in gMirabegron Q3FY27 onwards.
Though Lupin has some niche pipeline including 505 (b) (2) opportunity and biosimilars to compensate, we expect Lupin PAT to decline over FY26-28E. Our FY28E and FY29E EPS stands cut by 2-5 per cent. We maintain our "Accumulate" rating with TP of ₹2,250 (23x September 2028E EPS).
Revenues grew 14 per cent year on year to ₹7,780 crore, vs our estimate ₹7,600 crore. Beat was on account of higher-than-expected US sales which stood at $319 million, we estimated $290 million. Sequential decline was largely due to competition in certain key products. India formulation grew 15 per cent.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Line
Read the full, original unfiltered story directly on the publisher's portal.